HBV markers in haemodialysis Brazilian patients: a prospective 12-month follow-up
AUTOR(ES)
Moreira, Regina Célia, Deguti, Marta Mitiko, Lemos, Marcilio Figueiredo, Saraceni, Cláudia Patara, Oba, Isabel Takano, Spina, Angela Maria Miranda, Nascimento-Lima, Alessandra Stilhano, Fares, Jorge, Azevedo, Raymundo Soares, Gomes-Gouvêa, Michele Soares, Carrilho, Flair José, Pinho, João Renato Rebello
FONTE
Memórias do Instituto Oswaldo Cruz
DATA DE PUBLICAÇÃO
2010-02
RESUMO
The aim of this study was to determine the prevalence and the incidence of hepatitis B virus (HBV) among haemodialysis (HD) subjects and to evaluate whether testing for serological markers at the time of admission is suitable for HBV screening in this population. One hundred twenty-three patients belonging to two HD centres from São Paulo, Brazil, were tested prospectively. HBV DNA was detected by polymerase chain reaction (PCR) in each of the prospective subjects (n = 123) during one year. Additionally, all samples (n = 1,476) were analysed for HBV serological markers. The prevalence of hepatitis B core antibody (anti-HBc), hepatitis B surface antigen (HBsAg) and HBV DNA were 34.1%, 15.4% and 8.1%, respectively, while the incidence was null. Fluctuation in HBV serology was observed in one patient. Only 37.8% (17/45) of cases responded to the HBV vaccine. Our results suggest that employing more than one HBV marker and repeated follow-up evaluations may improve HBV screening in HD units.
Documentos Relacionados
- Delirium in elderly home-treated patients: a prospective study with 6-month follow-up
- Parent-assessed quality of life among adolescents undergoing orthodontic treatment: a 12-month follow-up
- Controlled clinical trial addressing teeth whitening with hydrogen peroxide in adolescents: a 12-month follow-up
- The effect of enamel matrix derivatives on root coverage: a 12-month follow-up of a randomized clinical trial
- Immediate loading implants with mandibular overdenture: a 48-month prospective follow-up study